Pharmacology/Pharmaceutical Industry
Review | Immune-checkpoint inhibitors: long-term implications of toxicity.
27 Jan, 2022 | 09:39h | UTCImmune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' https://t.co/7ymExYiqEY #ImmunoOnc #medonc pic.twitter.com/m6m92mZwOZ
— NatureRevClinOncol (@NatRevClinOncol) January 26, 2022
ESC Position Statement: Cardiovascular effects of doping substances, commonly prescribed medications, and ergogenic aids in relation to sports.
27 Jan, 2022 | 09:43h | UTCNews Release: Athletes warned against potential dangers of natural supplements – European Society of Cardiology
Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach.
27 Jan, 2022 | 09:18h | UTC
RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.
26 Jan, 2022 | 02:30h | UTCCommentaries:
Boosting immunity after CoronaVac – The Lancet
Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ
Commentary on Twitter
Heterologous boosting after 2 doses of #CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests. https://t.co/845JFnn3t7 pic.twitter.com/ibT3b5rs2K
— The Lancet (@TheLancet) January 23, 2022
As Pfizer and BioNTech begin a clinical trial of Omicron-based vaccine, the timeline to authorization is unclear.
26 Jan, 2022 | 02:20h | UTCSee also:
Pfizer begins testing omicron-matched COVID shots in adults – Associated Press
Pfizer and BioNTech start trials of new Omicron-specific jab – BBC
Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine – NPR
Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.
26 Jan, 2022 | 02:23h | UTCRelated:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
26 Jan, 2022 | 01:58h | UTC
Commentary on Twitter
In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266
— JAMA Network Open (@JAMANetworkOpen) January 20, 2022
Perspective: The value of patient-reported outcomes in early-phase clinical trials.
26 Jan, 2022 | 01:47h | UTCThe value of patient-reported outcomes in early-phase clinical trials – Nature Medicine (if the link is paywalled, try this one)
Commentary on Twitter
A @NatureMedicine Comment article argues that patient-reported outcomes, if used correctly, can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review. https://t.co/4ztwW76P2T pic.twitter.com/6sFRvswgJ2
— Nature Portfolio (@NaturePortfolio) January 24, 2022
Systematic Review: Oral antihistamine‐decongestant‐analgesic combinations for the common cold.
26 Jan, 2022 | 01:31h | UTCOral antihistamine‐decongestant‐analgesic combinations for the common cold – Cochrane Library
Commentary: Oral antihistamine-decongestant-analgesic combinations for the common cold – Cochrane Library
WHO drops opposition to boosters – recommends third Pfizer jab for adults & two vaccines for children ages 5 & up.
25 Jan, 2022 | 09:45h | UTCRelated:
WHO updated roadmap for prioritizing uses of COVID-19 vaccines.
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.
25 Jan, 2022 | 09:43h | UTCNews release: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians
Related:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
RCT: Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone for the treatment of gonorrhea.
25 Jan, 2022 | 09:20h | UTCEfficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q
— The Lancet HIV (@TheLancetHIV) January 24, 2022
Cohort study: In patients with a prosthetic joint, prophylactic antibiotics are probably not needed for invasive dental procedures.
25 Jan, 2022 | 09:11h | UTCCommentary: Prophylactic Antibiotics Not Needed Before Invasive Dental Procedures – HealthDay
Commentary on Twitter
Case-crossover study analyzing the incidence of invasive dental procedures (IDP) over the 15-months before 9,427 late prosthetic joint infection hospital admissions (LPJI) and found no evidence of a temporal association b/w IDP and LPJI. https://t.co/hcpwpN0B4H
— JAMA Network Open (@JAMANetworkOpen) January 19, 2022
Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.
24 Jan, 2022 | 08:56h | UTCCommentaries: New data show booster doses protect against Omicron – CIDRAP
Related CDC Studies:
Commentary on Twitter
Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL
— JAMA (@JAMA_current) January 21, 2022
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
24 Jan, 2022 | 08:35h | UTCWHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP
Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.
24 Jan, 2022 | 08:52h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ASPphysician/status/1484874519252721664
RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.
24 Jan, 2022 | 08:18h | UTCEfficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)
News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases
Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay
Clinical review of subcutaneous Semaglutide for obesity.
24 Jan, 2022 | 07:54h | UTC
A faster way to find good medical treatments is gaining ground – “A type of clinical trial that tests many therapies at once is being used for COVID and Alzheimer’s”.
24 Jan, 2022 | 07:50h | UTCA Faster Way to Find Good Medical Treatments Is Gaining Ground – Scientific American
Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials.
24 Jan, 2022 | 07:49h | UTC
Commentary from the author on Twitter (thread – click for more)
Our new paper is out now in @JAMANetworkOpen !
When a randomized trial designs a « Physicians’ choice » or « Investigators’ choice » control arm, you might think :
« Great, the control arm is standard of care ! »
➡️ you may be surprised 🧵👇🏻https://t.co/uho2pvXcG5— Timothée Olivier, MD (@Timothee_MD) January 21, 2022
RCT: Immunogenicity and reactogenicity of different vaccine boosters after a first J&J vaccine.
21 Jan, 2022 | 10:12h | UTC
Commentary on Twitter
Trial examined effects of boosting with one of the three approved #COVI19 vaccines — AD26.COV2.S, mRNA-1273, or BNT162b2 — 3 mos after the primary vaccination. All increased neutralizing-antibody levels & T-cell responses; mRNA vaccines were higher. https://t.co/qkpQFvNliJ pic.twitter.com/MUfa1OEsLP
— NEJM (@NEJM) January 19, 2022
Editorial | Covid-19 vaccines and treatments: we must have raw data, now.
21 Jan, 2022 | 10:00h | UTCCovid-19 vaccines and treatments: we must have raw data, now – The BMJ
News Release: Editors call for covid-19 vaccine and treatment data to be available for public scrutiny – The BMJ
Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.
21 Jan, 2022 | 09:53h | UTC
RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.
21 Jan, 2022 | 09:46h | UTCLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Commentary on Twitter
In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively. https://t.co/lzqFDnhAQn pic.twitter.com/Tm2BJZuh1D
— NEJM (@NEJM) January 19, 2022
Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.
21 Jan, 2022 | 09:50h | UTC